Pharmacological targeting of casein kinase 1δ suppresses oncogenic NRAS-driven melanoma
Sign Up to like & getrecommendations! Published in 2024 at "Nature Communications"
DOI: 10.1038/s41467-024-54140-1
Abstract: Activating mutations in NRAS account for 15–20% of melanoma, yet effective anti-NRAS therapies are still lacking. In this study, we unveil the casein kinase 1δ (CK1δ) as an uncharacterized regulator of oncogenic NRAS mutations, specifically… read more here.
Keywords: suppresses oncogenic; oncogenic nras; nras mutants; casein kinase ... See more keywords